NeurAxis (NRXS) Competitors $2.31 -0.05 (-1.91%) As of 02:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NRXS vs. CTSO, ICCM, ZYXI, SURG, NTRB, VANI, GUTS, HYPR, SPAI, and APTShould you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include Cytosorbents (CTSO), IceCure Medical (ICCM), Zynex (ZYXI), SurgePays (SURG), Nutriband (NTRB), Vivani Medical (VANI), Fractyl Health (GUTS), Hyperfine (HYPR), Safe Pro Group Inc. Common Stock (SPAI), and Alpha Pro Tech (APT). These companies are all part of the "medical equipment" industry. NeurAxis vs. Cytosorbents IceCure Medical Zynex SurgePays Nutriband Vivani Medical Fractyl Health Hyperfine Safe Pro Group Inc. Common Stock Alpha Pro Tech Cytosorbents (NASDAQ:CTSO) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Does the media prefer CTSO or NRXS? In the previous week, Cytosorbents had 3 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Cytosorbents and 0 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.91 beat Cytosorbents' score of 0.47 indicating that NeurAxis is being referred to more favorably in the news media. Company Overall Sentiment Cytosorbents Neutral NeurAxis Very Positive Which has better earnings and valuation, CTSO or NRXS? NeurAxis has lower revenue, but higher earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytosorbents$35.59M1.87-$28.51M-$0.38-2.80NeurAxis$2.69M6.19-$14.63M-$1.20-1.92 Is CTSO or NRXS more profitable? Cytosorbents has a net margin of -49.47% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity.Company Net Margins Return on Equity Return on Assets Cytosorbents-49.47% -118.54% -42.31% NeurAxis -492.76%N/A -641.25% Do insiders & institutionals have more ownership in CTSO or NRXS? 32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by insiders. Comparatively, 15.2% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, CTSO or NRXS? Cytosorbents has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.46, suggesting that its stock price is 246% more volatile than the S&P 500. Does the MarketBeat Community favor CTSO or NRXS? Cytosorbents received 440 more outperform votes than NeurAxis when rated by MarketBeat users. However, 100.00% of users gave NeurAxis an outperform vote while only 73.26% of users gave Cytosorbents an outperform vote. CompanyUnderperformOutperformCytosorbentsOutperform Votes44173.26% Underperform Votes16126.74% NeurAxisOutperform Votes1100.00% Underperform VotesNo Votes Do analysts rate CTSO or NRXS? Cytosorbents presently has a consensus target price of $4.67, suggesting a potential upside of 338.18%. Given Cytosorbents' stronger consensus rating and higher probable upside, research analysts clearly believe Cytosorbents is more favorable than NeurAxis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00NeurAxis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCytosorbents beats NeurAxis on 11 of the 19 factors compared between the two stocks. Get NeurAxis News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXS vs. The Competition Export to ExcelMetricNeurAxisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.24M$3.19B$5.50B$7.96BDividend YieldN/A1.80%5.11%4.23%P/E Ratio-1.2215.5022.6318.55Price / Sales6.1953.86397.30103.38Price / CashN/A44.0938.1834.62Price / Book-8.543.546.704.25Net Income-$14.63M$94.03M$3.23B$248.27M7 Day Performance-3.35%2.82%1.36%1.28%1 Month Performance9.50%6.04%3.85%3.75%1 Year Performance-30.15%-17.61%15.87%5.31% NeurAxis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXSNeurAxisN/A$2.31-1.9%N/A-26.6%$16.24M$2.69M-1.2219CTSOCytosorbents1.9401 of 5 stars$1.09-0.9%$4.67+328.1%+24.7%$68.13M$35.59M-3.03220ICCMIceCure Medical2.7177 of 5 stars$1.22+1.7%$2.50+104.9%+5.9%$67.71M$3.29M-4.2160Short Interest ↓News CoverageGap UpZYXIZynex2.6853 of 5 stars$2.24-7.1%$10.25+357.6%-84.9%$67.71M$192.35M14.93770Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeSURGSurgePays2.7271 of 5 stars$3.27-1.8%$8.75+167.6%-17.6%$66.75M$60.88M-2.8940Short Interest ↓NTRBNutriband2.8193 of 5 stars$5.84+9.8%$13.00+122.6%+98.3%$64.86M$2.02M-8.2310Earnings ReportNews CoverageGap UpVANIVivani Medical3.3014 of 5 stars$1.05flat$4.00+281.0%-36.4%$62.20MN/A-2.3320Positive NewsGUTSFractyl Health1.5963 of 5 stars$1.20-4.8%$11.00+816.7%-81.2%$58.70M$93,000.00-0.10102HYPRHyperfine3.5842 of 5 stars$0.74-1.6%$1.33+78.5%-10.5%$57.98M$12.89M-1.31190Short Interest ↓Positive NewsSPAISafe Pro Group Inc. Common StockN/A$3.39+3.7%N/AN/A$51.43M$2.17M0.0011Gap UpAPTAlpha Pro TechN/A$4.39-1.8%N/A-27.2%$47.73M$57.84M11.86120Analyst ForecastGap Down Related Companies and Tools Related Companies Cytosorbents Alternatives IceCure Medical Alternatives Zynex Alternatives SurgePays Alternatives Nutriband Alternatives Vivani Medical Alternatives Fractyl Health Alternatives Hyperfine Alternatives Safe Pro Group Inc. Common Stock Alternatives Alpha Pro Tech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRXS Stock Free NRXS Stock Alerts